Study on efficacy and safety of trastuzumab chemotherapy for the treatment of human epidermal growth factor receptor-2 positive breast cancer
10.13699/j.cnki.1001-6821.2015.09.014
- VernacularTitle:曲妥珠单抗新辅助化疗表皮生长因子受体2阳性乳腺癌的临床疗效及安全性评价
- Author:
Ke YIN
1
;
Yong-Jin CAO
Author Information
1. 宁波市第一医院 甲状腺乳腺外科
- Keywords:
breast cancer;
trastuzumab;
neoadjuvant chemotherapy;
human epidermal growth factor receptor 2;
clinical efficacy
- From:
The Chinese Journal of Clinical Pharmacology
2015;(9):725-727
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of neoadjuvantchemotherapy of trastuzumab combined with paclitaxel on human epidermalgrowth factor receptor -2 (HER2) positive breast cancer.Methods A total of 36 patients with breast cancer were included in this study.Patients in this study were given trastuzumab combined with paclitaxelneoadjuvant chemotherapy.Paclitaxel 175 mg· m-2 through intravenousinjection in 3 h on day 1 followed by trastuzumab 8 mg· kg-1 (burdendosage) on day 2 for cycle 1.And for cycle 2 to 4, paclitaxel remainedthe same, followed by trastuzumab 6 mg· kg-1 .Each chemotherapycycle was 21 days.After 4 cycles of chemotherapy treatment, the data ofclinical efficacy and toxicity were evaluated.Results All of the 36 casesfinished the neoadjuvant chemotherapy.The case of completeresponse, partial response were 18 and 13 and and objective responserate (ORR) was 86.11%.There was no statistical difference in ORRamong the subgroup analysis (P >0.05).The main adverse reactionswere granulocytopenia (13.88%) and fatigue (61.11%) during thechemotherapy.Conclusion High clinical efficacy and less adversereactions are found in the treatment of trastuzumab combined withpaclitaxel for HER2 -positive breast cancer.
